Intravail: highly effective intranasal delivery of peptide and protein drugs.
Intravail: highly effective intranasal delivery of peptide and protein drugs.
复制标题
DOI：
10.1517/17425247.3.4.529
复制
发表时间：
2006-07-01
影响因子：
6.6
通讯作者：
Maggio, Edward T
中科院分区：
文献类型：
--
作者：
Maggio, Edward T
最近开发了一类新的专利烷基糖透粘膜递送增强剂，统称为Intravail（Aegis Therapeutics）吸收增强剂，为广泛的人类疾病的新治疗选择创造了机会。与通过注射蛋白质、肽和其他大分子治疗剂获得的生物利用度相比，分娩内吸收促进剂提供了无与伦比的鼻内生物利用度。这些新型、高效且无刺激性的辅料克服了鼻内给药的两个主要限制，即粘膜刺激和生物利用度差，并为患者和医生提供了更方便、更有效和更安全的治疗方法。对于制药公司来说，Intravail提供了一种利用两个重要行业动态的方法：快速增长的肽和蛋白质药物商业化的行业兴趣，以及对全身药物递送的鼻内途径的兴趣和使用的增加。
Recent development of a new class of patented alkylsaccharide transmucosal delivery enhancement agents, collectively designated as Intravail (Aegis Therapeutics) absorption enhancers, has created opportunities for new therapeutic options across a broad spectrum of human diseases. Intravail absorption enhancers provide unsurpassed intranasal bioavailabilities, comparable to those that are achieved by injection for protein, peptide and other macromolecular therapeutics. These novel, highly effective and non-irritating excipients circumvent the two primary limitations of intranasal drug delivery, namely mucosal irritation and poor bioavailability, and offer the promise of more convenient, more effective and safer therapeutics for patients and physicians alike. For pharmaceutical companies, Intravail provides a means to capitalise on two important industry dynamics: rapidly growing industry interest in commercialising peptide and protein drugs, and increasing interest in, and use of, the intranasal route for systemic drug delivery.